NASDAQ : VALN

Valneva SE

$5.3 USD

$0 (0.0%)

Volume
49.08K
Average Volume
29.61K
Market Capitalization
$502.56M
P/E Ratio
-3.10
Dividend Yield
0.00%
Price Target
$11.00
Year High
$12.25
Year Low
$4.75
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.14
Company Overview

NASDAQ

Thomas Lingelbach

Biotechnology

Healthcare

VALN

674

FR

USD

https://valneva.com

33 2 28 07 37 10

92025Y103

0001836564

Liquidity Metrics

2.73

2.14

1.60

1.12

0.00

Sales & Valuation

$174.66M

3.05

5.65

-6.90

-0.80

Profitability

-$1.32

-$115.19M

-88.30%

-88.03%

-106.22%

-37.10%

P/E Metrics

-3.10

0.06

0.06

Analyst Price Target & Rating

$11.00

$11.00

$11.00

Strong Sell

1/5

3 Analysts

-51.82%

Financial Health Scores

-1.86

1/9

$107.33M

$372.4M

$295.31M

-$93.68M

Key Metrics (TTM)

$543.46M

3.48

-6.28

2.14

-106.22%

-36.00%

-34.63%

-15.74%

119 days

Company Executives
Name Title
Juan-Carlos Jaramillo Chief Medical Officer
Kendra Wergin General Counsel & Corporate Secretary
Hanneke Schuitemaker Chief Scientific Officer
Joshua Drumm Vice President of Investor Relations
Peter Buhler Chief Financial Officer
Thomas Lingelbach President, Chief Executive Officer & Director
Vincent Dequenne Chief Operating Officer
Dipal Patel Chief Commercial Officer
Laetitia Bachelot-Fontaine Vice President of Global Communications & European Investor Relations
Petra Pesendorfer Chief People Officer
Poll Results

No votes yet today — be the first to share your view!

About Valneva SE (NASDAQ:VALN) Stock

Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is ... being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.

Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026

2026-07-22 11:45:00

Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its first half 2026 financial results on Thursday, August 13, 2026. The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update.

Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

2026-06-25 13:52:09

Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript

Valneva Announces Successful Outcome of its Annual General Meeting

2026-06-25 11:45:00

Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company's Annual General Meeting (AGM), held earlier today in Lyon, France. Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors regarding the Company's share capital, and the transfer of Valneva's registered office to Lyon following the closure of its Nantes site.

Valneva Announces Availability of Documentation for its Annual General Meeting

2026-06-04 01:00:00

Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Annual General Meeting (“the Meeting”) to be held on June 25, 2026 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France).

Valneva to Participate at U.S. and European Investor Conferences in June

2026-05-28 11:45:00

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

Valneva to Participate at U.S. and European Investor Conferences in June

2026-05-28 11:45:00

Lyon (France), May 28, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe

2026-05-28 11:45:00

Lyon (France), le 28 mai 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante participeront, en juin 2026, à plusieurs conférences aux États-Unis et en Europe, au cours desquelles ils feront des présentations et rencontreront des investisseurs institutionnels.

Valneva Q1 Earnings Call Highlights

2026-05-13 15:12:54

Valneva NASDAQ: VALN reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer.

Frequently Asked Questions

What is the current Valneva SE (VALN) stock price?

Valneva SE(NASDAQ:VALN) stock price is $5.3 in the last trading session. During the trading session, VALN stock reached the peak price of $12.25 while $4.75 was the lowest point it dropped to. The percentage change in VALN stock occurred in the recent session was 0.0% while the dollar amount for the price change in VALN stock was $0.

VALN's industry and sector of operation?

The NASDAQ listed VALN is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of VALN?

Juan-Carlos Jaramillo | Chief Medical Officer
Kendra Wergin | General Counsel & Corporate Secretary
Hanneke Schuitemaker | Chief Scientific Officer
Joshua Drumm | Vice President of Investor Relations
Peter Buhler | Chief Financial Officer

How many employees does VALN have?

Number of VALN employees currently stands at 674. VALN operates from 6 rue Alain Bombard, Saint-Herblain, GE 44800, FR.

Link for VALN official website?

Official Website of VALN is: https://valneva.com

How do I contact VALN?

VALN could be contacted at phone #33 2 28 07 37 10 and can also be accessed through its website. VALN operates from 6 rue Alain Bombard, Saint-Herblain, GE 44800, FR.

How many shares of VALN are traded daily?

The average number of VALN shares traded daily for last 3 months was 29.61K.

What is the market cap of VALN currently?

The market value of VALN currently stands at $502.56M with its latest stock price at $5.3